- |||||||||| Clinical, Journal: Sarcopenia Definitions and Their Associations With Mortality in Older Australian Women. (Pubmed Central) - Apr 15, 2020
Unlike FNIH, the EWGSOP sarcopenia definition incorporating weak muscle strength and/or poor physical function was related to prognosis, as was the regionally adapted version of EWGSOP. Although sarcopenia definitions were not developed based on prognosis, this is an important consideration for globally standardizing the sarcopenia framework.
- |||||||||| Journal: Prevalance of sarcopenia according to decade. (Pubmed Central) - Apr 14, 2020
Although sarcopenia definitions were not developed based on prognosis, this is an important consideration for globally standardizing the sarcopenia framework. Identification of sarcopenia prevalence in our population is important due to limitations of treatment administered after diagnosis is made.
- |||||||||| Review, Journal: Lipotoxicity, aging, and muscle contractility: does fiber type matter? (Pubmed Central) - Apr 14, 2020
In this perspective, we briefly review the age-related physiological changes in cellularity, secretory profiles, and inflammatory status of adipose tissue which drive lipotoxicity (spillover) of skeletal muscle and then provide evidence of how this may affect specific fiber type contractility. We focus on biological contributors (cellular machinery) to contractility for which there is some evidence of vulnerability to lipid stress distinguishing between fiber types.
- |||||||||| Clinical, Journal: Software for the Diagnosis of Sarcopenia in Community-Dwelling Older Adults: Design and Validation Study. (Pubmed Central) - Apr 14, 2020
We developed and validated a software for the diagnosis of sarcopenia in older Chilean adults that can be used on a mobile device or a computer with good sensitivity and specificity, thus allowing for the development of programs for the prevention, delay, or reversal of this disease. To our knowledge, HTSMayor is the first software to diagnose sarcopenia.
- |||||||||| Journal: 'Maintaining Muscle Function Across the Lifespan: The State of Science'. (Pubmed Central) - Apr 14, 2020
Great strides have been made to improve screening procedures and diagnostic criteria for sarcopenia, but continued optimization of diagnostic and screening strategies is needed to better identify individuals with sarcopenia or at risk of developing sarcopenia. Understanding and addressing the major drivers of sarcopenia pathogenesis will help develop therapeutics that can reduce the impact of sarcopenia on affected individuals and society.
- |||||||||| Review, Journal: Roles of myokines in exercise-induced improvement of neuropsychiatric function. (Pubmed Central) - Apr 12, 2020
Therefore, more clinical evidences for the association of myokine release after exercise and their effect on the brain function are required. Finally, we discuss the effect size of the action of myokines on cognitive benefits of exercise, in addition to other contributors, such as improvement of the cardiovascular system or the effect of "exercise factors" released from non-muscle organs, particularly in patients with sarcopenia.
- |||||||||| Journal: Parkin sarcopenia in its tracks by improving mitochondrial health. (Pubmed Central) - Apr 12, 2020
Finally, we discuss the effect size of the action of myokines on cognitive benefits of exercise, in addition to other contributors, such as improvement of the cardiovascular system or the effect of "exercise factors" released from non-muscle organs, particularly in patients with sarcopenia. No abstract available
- |||||||||| Journal: Clusterin silencing restores myoblasts viability and down modulates the inflammatory process in osteoporotic disease. (Pubmed Central) - Apr 12, 2020
Results obtained suggest a potential role of CLU in OP by influencing myoblasts terminal differentiation, epigenetic regulation of muscle cell differentiation and senescence. Moreover, CLU silencing points out its role in the modulation of tissue damage repair and inflammation, proposing it as a new diagnostic marker for muscle degeneration and a potential target for specific therapeutic intervention in OP related sarcopenia.
- |||||||||| Clinical, Review, Journal: Predictors of poor functional outcomes and mortality in patients with hip fracture: a systematic review. (Pubmed Central) - Apr 12, 2020
This systematic review identified multiple significant predictors of poor functional outcomes and mortality, with the hand grip strength and frailty being important emerging predictors in the most recent literature. These predictors would further inform healthcare providers of their patients' health status and allow for early intervention for modifiable predictors.
- |||||||||| Review, Journal: Multidimensional Approach to Frailty. (Pubmed Central) - Apr 11, 2020
Many of the determinants of the FS have already been known: reduction in physical activity, malnutrition, sarcopenia, polypharmacy, depressive symptom, cognitive disorders, and lack of social support. This review shows that insight into FS determinants is the starting point for building both the comprehensive definition of FS and the adoption of the assessment method of FS, and then successful clinical management.
- |||||||||| Clinical, Journal: Improved strength prediction combining clinically available measures of skeletal muscle mass and quality. (Pubmed Central) - Apr 10, 2020
The hypothesis of the current study was confirmed, strongly supporting and extending earlier reports by quantifying the combined independent effects of skeletal muscle mass and quality on lower-body and upper-body measures of strength. These observations provide a clinically available method for future research aimed at optimizing sarcopenia and frailty risk prediction models.
- |||||||||| Clinical, Journal: Muscle mass measures and incident osteoporosis in a large cohort of postmenopausal women. (Pubmed Central) - Apr 10, 2020
However, when systemic inflammation coincides with sarcopenia and/or low VAT, prognosis is adversely affected, independent of the Fong clinical prognostic score. Muscle mass measures adjusted for height only (SMM/ht , aSMM/ht ) appear to be better muscle-relevant risk factors for incident osteoporosis in postmenopausal women, including when stratified into lean participants and participants with increased adiposity.
- |||||||||| Review, Journal: D -Creatine dilution and the importance of accuracy in the assessment of skeletal muscle mass. (Pubmed Central) - Apr 10, 2020
Inaccurate measurements of muscle mass by DXA and other methods have led to inconsistent results and potentially erroneous conclusions about the importance of skeletal muscle mass in health and disease. The assessment of skeletal muscle mass using the D -Cr dilution method in prospective cohort studies may reveal sarcopenia as a powerful risk factor for late life disability and chronic disease.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Exercise-induced AMPK activation is involved in delay of skeletal muscle senescence. (Pubmed Central) - Apr 10, 2020
In this study, we provide new evidence that prior activation of AMPK can reduce doxorubicin induced cell senescence phenotypes. The evidence in this paper suggest that aerobic exercise-activated catabolism in the skeletal muscle may prevent cellular senescence, partially through the cell cycle regulation.
- |||||||||| Ocuvia (elamipretide) / Stealth BioTherapeutics, Sarconeos (BIO101) / Biophytis
Journal: Recent developments in the field of cachexia, sarcopenia, and muscle wasting: highlights from the 11th Cachexia Conference. (Pubmed Central) - Apr 10, 2020
Clinical studies that investigated novel approaches, including urolithin A, the role of gut microbiota, metal ion transporter ZIP14, lysophosphatidylcholine and lysophosphatidylethanolamine, and BIO101, were described. It remains a fact, however, that effective treatments of cachexia and wasting disorders are urgently needed in order to improve patients' quality of life and their survival.
- |||||||||| Review, Journal: From molecular promise to preclinical results: HDAC inhibitors in the race for healthy aging drugs. (Pubmed Central) - Apr 10, 2020
Furthermore, we explore potential mechanisms of how HDAC inhibitors may have such a strong grasp on health and longevity, summarizing their links to other hallmarks of aging. Finally, we show the wide range of age-related preclinical disease models, ranging from neurodegeneration to heart disease, diabetes to sarcopenia, which show improvement upon HDAC inhibition.
- |||||||||| Review, Journal: Sarcopenia and fatty liver disease. (Pubmed Central) - Apr 10, 2020
This review discusses the concept and diagnosis of sarcopenia and NAFLD, common pathophysiology, and clinical studies linking sarcopenia to NAFLD. The presentation of the association between sarcopenia and NAFLD may provide an opportunity to prevent the deterioration of fatty liver disease.
- |||||||||| Clinical, Journal: An Innovative AAL System Based on IoT Technologies for Patients with Sarcopenia. (Pubmed Central) - Apr 10, 2020
Test beds have been carried out by using the independent replications method, and all measurements related to the identified sarcopenia parameters are characterized by a 95% confidence interval with a 5% maximum relative error. The implementation of these technologies as a supporting clinical tool used in a specific setting could significantly impact the life and independence of the sarcopenic frail elderly population.
- |||||||||| Journal: Mitochondrial oxidative capacity and NAD biosynthesis are reduced in human sarcopenia across ethnicities. (Pubmed Central) - Apr 10, 2020
These changes translate functionally into fewer mitochondria, reduced mitochondrial respiratory complex expression and activity, and low NAD levels through perturbed NAD biosynthesis and salvage in sarcopenic muscle. We provide an integrated molecular profile of human sarcopenia across ethnicities, demonstrating a fundamental role of altered mitochondrial metabolism in the pathological loss of skeletal muscle mass and function in older people.
- |||||||||| Clinical, Journal: Bone Mass Loss and Sarcopenia in Ecuadorian Patients. (Pubmed Central) - Apr 9, 2020
It is clear that the prevalence of sarcopenia is higher in patients with greater loss of bone mass. Identifying pathways that affect both bone and muscle could facilitate the development of treatments that simultaneously improve osteoporosis and sarcopenia.
- |||||||||| Review, Journal: Selective androgen receptor modulators: the future of androgen therapy? (Pubmed Central) - Apr 9, 2020
While there are no indications for SARMs currently approved by the Food and Drug Administration (FDA), many potential applications are still being explored, and results are promising. In this review, we examine the literature assessing the use of SARMS for a number of indications.
- |||||||||| Clinical, Review, Journal: Assessment of body composition and impact of sarcopenia and sarcopenic obesity in patients with gastric cancer. (Pubmed Central) - Apr 9, 2020
To improve the short- and long-term outcomes of patients with GC and sarcopenia, adequate energy and protein intake are necessary during resistance training. In the present study, we performed a literature review and presented a method to evaluate body composition, the relationship between skeletal muscle mass and GC, and perioperative nutrition and exercise therapy for patients with sarcopenia.
- |||||||||| Trial suspension: Identifying Therapeutic Targets of Accelerated Sarcopenia (clinicaltrials.gov) - Apr 9, 2020
P=N/A, N=102, Suspended,
In the present study, we performed a literature review and presented a method to evaluate body composition, the relationship between skeletal muscle mass and GC, and perioperative nutrition and exercise therapy for patients with sarcopenia. Recruiting --> Suspended
- |||||||||| Muscle mass on MRI predicts HCC survival following yttrium-90 radioembolization (Room 606 ) - Apr 8, 2020 - Abstract #SIR2020SIR_35;
Muscle mass on pre-procedure MRI predicts survival in patients with hepatocellular carcinoma undergoing yttrium-90 radioembolization. Sarcopenia may be associated with shorter survival and ongoing analysis of additional patients will improve study power to detect significant differences.
- |||||||||| Trial completion date: Muscle Capillarization and Sarcopenia (clinicaltrials.gov) - Apr 8, 2020
P=N/A, N=40, Recruiting,
Sarcopenia may be associated with shorter survival and ongoing analysis of additional patients will improve study power to detect significant differences. Trial completion date: Sep 2022 --> Apr 2022
- |||||||||| NN1213 / Novo Nordisk
Biomarker, Enrollment closed, Trial completion date: HAPPY: A Prospective Cohort Study of Aged People for Chronic Diseases (clinicaltrials.gov) - Apr 8, 2020
P=N/A, N=1000, Active, not recruiting,
Trial completion date: Sep 2022 --> Apr 2022 Recruiting --> Active, not recruiting | Trial completion date: Jun 2020 --> Dec 2020
|
